Skip to main content
ModernaLaunch

Moderna's Flu Shot Now Has a Wall Street Backer - and a Cost Bill That Shrinks by $200 Million

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

Moderna received FDA clearance for its flu shot, mFLUSIVA, marking its fifth commercialized product worldwide.

Source

Article excerpt

Moderna closed its third quarter of 2026 with a profit, a raised sales outlook, and a new product approval in hand. Yet the detail that may matter most to shareholders sits further down the income statement: the company is spending far less on research than it was a year ago, and a private equity giant is now shouldering part of the development bill. Moderna posted revenue of $1.3 billion for the three months, up 29% from a year earlier. Net income came in at $162 million on a GAAP basis, a sharp reversal from the $200 million loss recorded in the third quarter of 2025. Diluted earnings per share reached $0.38. Higher international sales of COVID-19 vaccines and payments tied to government partnerships underpinned the quarter, according to Reuters. Those long-term government agreements also contributed to top-line growth. The stock responded with a 5.7% advance following the release. Management now guides toward 15%–25% revenue growth for the full year 2026, a substantial upgrade from the maximum of 10% previously held out. The company also trimmed its outlook for operating expenses by roughly $0.2 billion. Should investors sell immediately? Or is it worth buying Moderna? Research and development costs totaled $583 million in the quarter, down 27% year over year. Lower outlays for clinical trials, personnel and stock-based compensation all played a part. For the full year...

Keep reading with a free account

The rest of this article, and every signal for Moderna, is in your free account.

Extracted from this sentence

The FDA's clearance of mFLUSIVA, announced yesterday, makes it the fifth product Moderna has brought to market worldwide, according to the company.

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
mFLUSIVA
Takes effect
Nov 6, 2026

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 7, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/cc7a5e79-b1ff-6aed-3242-ff190bec2386 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "cc7a5e79-b1ff-6aed-3242-ff190bec2386",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-11-07T13:11:39+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/moderna-s-flu-shot-now-has-a-wall-street-backer-and-a-cost-bill-that-shrinks-by-200-million/70474629",
    "title": "Moderna's Flu Shot Now Has a Wall Street Backer - and a Cost Bill That Shrinks by $200 Million - ad-hoc-news.de",
    "excerpt": "Moderna closed its third quarter of 2026 with a profit, a raised sales outlook, and a new product approval in hand. Yet the detail that may matter most to shareholders sits further down the income statement: the company is spending far less on research than it was a year ago, and a private equity giant is now shouldering part of the development bill. Moderna posted revenue of $1.3 billion for the three months, up 29% from a year earlier. Net income came in at $162 million on a GAAP basis, a sharp reversal from the $200 million loss recorded in the third quarter of 2025. Diluted earnings per share reached $0.38. Higher international sales of COVID-19 vaccines and payments tied to government partnerships underpinned the quarter, according to Reuters. Those long-term government agreements also contributed to top-line growth. The stock responded with a 5.7% advance following the release. Management now guides toward 15%–25% revenue growth for the full year 2026, a substantial upgrade from the maximum of 10% previously held out. The company also trimmed its outlook for operating expenses by roughly $0.2 billion. Should investors sell immediately? Or is it worth buying Moderna? Research and development costs totaled $583 million in the quarter, down 27% year over year. Lower outlays for clinical trials, personnel and stock-based compensation all played a part. For the full year...",
    "product": "mFLUSIVA",
    "summary": "Moderna received FDA clearance for its flu shot, mFLUSIVA, marking its fifth commercialized product worldwide.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2843964_1920_1080.webp",
    "confidence": 0.95,
    "product_data": {
      "name": "mFLUSIVA",
      "full_text": "mFLUSIVA, the newly approved flu shot",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-07T13:11:39Z",
    "effective_date": "2026-11-06",
    "article_sentence": "The FDA's clearance of mFLUSIVA, announced yesterday, makes it the fifth product Moderna has brought to market worldwide, according to the company."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.